Press Releases

Gives Veterinarians New Choice to Treat Fleas, Ticks and Sarcoptic Mange in Dogs Aged Eight Weeks and Older Innovation from Zoetis Targets Growing Demand for Oral Flea and Tick Medication Zoetis Inc. today announced that the European Commission has granted marketing authorization for Simparica TM (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age. The approval follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in September 2015. “The approval of Simparica gives veterinarians a new oral choice in parasite control for dogs,” said Dr. Balázs Capári, veterinary specialist, small animal medicine, in Sümeg, Hungary, who participated in clinical trials of Simparica.1 “In my experience, Simparica has been shown to rapidly kill fleas and ticks with efficacy that persists for five weeks. Dog owners participating in the trials also reported that Simparica ...

Sydney, New South Wales, Australia - August 5, 2015 – Zoetis today announced that the Hendra virus vaccine,Equivac ® HeV, has received registration from the Australian Pesticides and Veterinary Medicines Authority (APVMA). “We at Zoetis are pleased that after nearly three years of positive uptake, Equivac® HeV vaccine has successfully been registered,” said Lance Williams, General Manager for Zoetis in Australia and New Zealand. “The APVMA undertakes one of the most detailed assessment processes in the world before approving registration of a product and Equivac HeV passed every assessment criteria for registration. Equivac HeV demonstrates Zoetis’ commitment to providing horse owners with quality animal health solutions they can count on.” Equivac HeV was first made available in November 2012, in response to the growing number of outbreaks and subsequent horse deaths in Queensland and New South Wales.  The full registration comes one week after reports of a second Hendra virus ...

First targeted antibody therapy approved for control of clinical signs of atopic dermatitis in dogs Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. It represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientific insights into the pathway of allergic skin conditions. “The introduction of Canine Atopic Dermatitis Immunotherapeutic* will provide veterinarians an innovative new option to address this very challenging skin condition,” said Thomas Lewis II, DVM, DACVD, who participated in clinical studies of this antibody therapy and is a veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz.** “By helping to relieve itching and the clinical signs associated ...

LONDON, UK - March 19, 2015 - Leading animal health company Zoetis Inc. unveiled its Centre for Digital Innovation (CDI) at the House of Lords today. Opened in the heart of London’s Tech City, the new Centre will create sophisticated digital products that enable data-driven decision-making to enhance precision farming and improve animal wellbeing for livestock and pets. Hosted by Lord Trees, the event was introduced by Lord de Mauley and attended by industry representatives including the National Farmers Union and those with an interest in the success of UK farming, among them some of the large supermarket chains. The production of high-quality food for an expanding population in a world of finite resources has put precision farming firmly on the Centre’s agenda. The statistics are compelling: a global population increase of 30% between 1990 and 2010 2 has led to a greater demand for animal protein and need for productivity improvements; seven billion people worldwide consume protein ...

Zoetis Inc . (NYSE:ZTS) today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements. The purchase expands Zoetis’ companion animal product portfolio to bring veterinarians solutions for anesthesia and treating pain and serious illnesses such as diabetes. It also brings novel cancer and pain compounds to the Zoetis pipeline for further development. “We believe Zoetis’ scale, industry-leading field force, and global presence will rapidly expand the reach and penetration of these newly acquired, leading brands for the veterinary surgical suite,” said Zoetis Group President Kristin Peck, who oversees the company’s Strategy and Corporate Development organization. “The acquisition is a prime example of our value creation strategy to deploy capital to acquire products that enhance our portfolio and enable us to deliver more customized solutions to veterinarians.” In conjunction with ...

Findings Published in Journal of Community and Supportive Oncology Are First to Show Improvement in Emotional Well-Being and Quality of Life Trial Conducted at Mount Sinai Beth Israel with Support from The Good Dog Foundation, Zoetis and Pfizer Foundation New York, NY – January 13, 2015 — Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients. The research was made available this week in the Journal of Community and Supportive Oncology . The study, conducted by researchers at Mount Sinai Beth Israel, found that patients receiving intensive multi-modal concomitant radiation therapy and chemotherapy for gastrointestinal, head or neck cancers experienced increases in emotional well-being and quality of life when they received visits from a certified therapy dog during the course of their treatment. Increases in emotional well-being were ...